⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RNXT News
RenovoRx, Inc. Common Stock
RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum
globenewswire.com
RNXT
RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
globenewswire.com
RNXT
RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
globenewswire.com
RNXT
RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer
globenewswire.com
RNXT
RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th
globenewswire.com
RNXT
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer
globenewswire.com
RNXT
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
globenewswire.com
RNXT
Form 8-K
sec.gov
RNXT
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment
globenewswire.com
RNXT
Form 8-K/A
sec.gov
RNXT